THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Michael Cookson to Urinary Bladder Neoplasms

This is a "connection" page, showing publications Michael Cookson has written about Urinary Bladder Neoplasms.
Connection Strength

13.073
  1. Editorial Comment. J Urol. 2018 08; 200(2):290-291.
    View in: PubMed
    Score: 0.533
  2. Radical Cystectomy-The Waiting is the Hardest Part…or is it? J Urol. 2016 04; 195(4 Pt 1):821-2.
    View in: PubMed
    Score: 0.451
  3. Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides. Eur Urol. 2015 Jan; 67(1):165-170.
    View in: PubMed
    Score: 0.393
  4. Surgical and chemotherapeutic management of regional lymph nodes in bladder cancer. J Urol. 2012 Oct; 188(4):1081-8.
    View in: PubMed
    Score: 0.356
  5. Lymph node yield at radical cystectomy predicts mortality in node-negative and not node-positive patients. Urology. 2012 Sep; 80(3):632-40.
    View in: PubMed
    Score: 0.353
  6. National practice patterns for immediate postoperative instillation of chemotherapy in nonmuscle invasive bladder cancer. J Urol. 2012 May; 187(5):1571-6.
    View in: PubMed
    Score: 0.345
  7. The relationship between perioperative blood transfusion and overall mortality in patients undergoing radical cystectomy for bladder cancer. Urol Oncol. 2013 Aug; 31(6):871-7.
    View in: PubMed
    Score: 0.333
  8. Predicting the probability of 90-day survival of elderly patients with bladder cancer treated with radical cystectomy. J Urol. 2011 Sep; 186(3):829-34.
    View in: PubMed
    Score: 0.330
  9. Early and late perioperative outcomes following radical cystectomy: 90-day readmissions, morbidity and mortality in a contemporary series. J Urol. 2010 Oct; 184(4):1296-300.
    View in: PubMed
    Score: 0.310
  10. Urinary diversion trends at a high volume, single American tertiary care center. J Urol. 2009 Nov; 182(5):2369-74.
    View in: PubMed
    Score: 0.291
  11. Outcomes of patients undergoing radical cystoprostatectomy for bladder cancer with prostatic involvement on final pathology. BJU Int. 2009 Oct; 104(8):1091-7.
    View in: PubMed
    Score: 0.282
  12. Urothelial carcinoma of the bladder metastatic to bone marrow presenting as isolated thrombocytopenia. ScientificWorldJournal. 2007 Jun 12; 7:1000-3.
    View in: PubMed
    Score: 0.248
  13. Non-muscle-invasive bladder cancer: the role of radical cystectomy. Urology. 2005 Nov; 66(5):917-22.
    View in: PubMed
    Score: 0.222
  14. Radical cystectomy for bladder cancer: the case for early intervention. Urol Clin North Am. 2005 May; 32(2):147-55.
    View in: PubMed
    Score: 0.215
  15. The surgical management of muscle invasive bladder cancer: a contemporary review. Semin Radiat Oncol. 2005 Jan; 15(1):10-8.
    View in: PubMed
    Score: 0.210
  16. Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Gu?rin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. J Urol. 2024 Jul; 212(1):74-86.
    View in: PubMed
    Score: 0.200
  17. Advances in diagnosis and treatment of bladder cancer. BMJ. 2024 02 12; 384:e076743.
    View in: PubMed
    Score: 0.197
  18. Health related quality of life in patients treated with radical cystectomy and urinary diversion for urothelial carcinoma of the bladder: development and validation of a new disease specific questionnaire. J Urol. 2003 Nov; 170(5):1926-30.
    View in: PubMed
    Score: 0.193
  19. Decreasing blood loss in patients treated with radical cystectomy: a prospective randomizes trial using a new stapling device. J Urol. 2003 Mar; 169(3):951-4.
    View in: PubMed
    Score: 0.185
  20. Impact of Maximal Transurethral Resection on Pathological Outcomes at Cystectomy in a Large, Multi-institutional Cohort. J Urol. 2023 05; 209(5):882-889.
    View in: PubMed
    Score: 0.184
  21. Complications of radical cystectomy for nonmuscle invasive disease: comparison with muscle invasive disease. J Urol. 2003 Jan; 169(1):101-4.
    View in: PubMed
    Score: 0.183
  22. Multicenter evaluation of neoadjuvant and induction gemcitabine-carboplatin versus gemcitabine-cisplatin followed by radical cystectomy for muscle-invasive bladder cancer. World J Urol. 2022 Nov; 40(11):2707-2715.
    View in: PubMed
    Score: 0.179
  23. Pathological findings of gynecologic organs obtained at female radical cystectomy. J Urol. 2002 Jul; 168(1):147-9.
    View in: PubMed
    Score: 0.176
  24. Health related quality of life assessment after radical cystectomy: comparison of ileal conduit with continent orthotopic neobladder. J Urol. 2002 Jul; 168(1):164-7.
    View in: PubMed
    Score: 0.176
  25. Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group. Eur Urol Oncol. 2022 Oct; 5(5):505-516.
    View in: PubMed
    Score: 0.176
  26. Eosinophilic cystitis presenting as a recurrent symptomatic bladder mass following intravesical mitomycin C therapy. J Urol. 2002 Apr; 167(4):1795.
    View in: PubMed
    Score: 0.173
  27. Carcinoma in situ and tumor multifocality predict the risk of prostatic urethral involvement at radical cystectomy in men with transitional cell carcinoma of the bladder. J Urol. 2002 Feb; 167(2 Pt 1):502-5.
    View in: PubMed
    Score: 0.171
  28. Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. Eur Urol. 2022 03; 81(3):223-228.
    View in: PubMed
    Score: 0.170
  29. Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer. J Urol. 2022 01; 207(1):70-76.
    View in: PubMed
    Score: 0.166
  30. Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer. World J Urol. 2021 Dec; 39(12):4345-4354.
    View in: PubMed
    Score: 0.166
  31. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol. 2001 Aug; 166(2):490-3.
    View in: PubMed
    Score: 0.165
  32. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021 01; 22(1):107-117.
    View in: PubMed
    Score: 0.158
  33. Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis. BJU Int. 2021 07; 128(1):79-87.
    View in: PubMed
    Score: 0.158
  34. Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma. BJU Int. 2021 05; 127(5):528-537.
    View in: PubMed
    Score: 0.157
  35. Nomogram Predicting Bladder Cancer-specific Mortality After Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-invasive Bladder Cancer: Results of an International Consortium. Eur Urol Focus. 2021 Nov; 7(6):1347-1354.
    View in: PubMed
    Score: 0.155
  36. Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer. Urol Oncol. 2020 07; 38(7):639.e1-639.e9.
    View in: PubMed
    Score: 0.149
  37. The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy. Urol Oncol. 2020 01; 38(1):3.e17-3.e27.
    View in: PubMed
    Score: 0.147
  38. Predictors of Recurrence, and Progression-Free and Overall Survival following Open versus Robotic Radical Cystectomy: Analysis from the RAZOR Trial with a 3-Year Followup. J Urol. 2020 03; 203(3):522-529.
    View in: PubMed
    Score: 0.145
  39. Risk of Ovarian Malignancy in Patients Undergoing Radical Cystectomy for Bladder Cancer. Urology. 2019 Jan; 123:181-185.
    View in: PubMed
    Score: 0.136
  40. Epidemiology, prevention, screening, diagnosis, and evaluation: update of the ICUD-SIU joint consultation on bladder cancer. World J Urol. 2019 Jan; 37(1):3-13.
    View in: PubMed
    Score: 0.135
  41. Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial. Lancet. 2018 06 23; 391(10139):2525-2536.
    View in: PubMed
    Score: 0.133
  42. Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy. World J Urol. 2019 Jan; 37(1):165-172.
    View in: PubMed
    Score: 0.133
  43. Optimal Trial Design for Studying Urinary Markers in Bladder Cancer: A Collaborative Review. Eur Urol Oncol. 2018 08; 1(3):223-230.
    View in: PubMed
    Score: 0.132
  44. Improving the quality of operative reports for transurethral resection of bladder tumor surgery in resident education. Can J Urol. 2017 Oct; 24(5):8976-8981.
    View in: PubMed
    Score: 0.127
  45. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol. 1997 Jul; 158(1):62-7.
    View in: PubMed
    Score: 0.125
  46. Minimally Invasive Versus Open Approach for Cystectomy: Trends in the Utilization and Demographic or Clinical Predictors Using the National Cancer Database. Urology. 2017 May; 103:99-105.
    View in: PubMed
    Score: 0.121
  47. Oncologic Outcomes after Anterior Exenteration for Muscle Invasive Bladder Cancer in Women. J Urol. 2016 Oct; 196(4):1030-5.
    View in: PubMed
    Score: 0.115
  48. A 10-Item Checklist Improves Reporting of Critical Procedural Elements during Transurethral Resection of Bladder Tumor. J Urol. 2016 Oct; 196(4):1014-20.
    View in: PubMed
    Score: 0.114
  49. Short term complications from transurethral resection of bladder tumor. Can J Urol. 2016 Apr; 23(2):8198-203.
    View in: PubMed
    Score: 0.114
  50. Loss of FOXA1 Drives Sexually Dimorphic Changes in Urothelial Differentiation and Is an Independent Predictor of Poor Prognosis in Bladder Cancer. Am J Pathol. 2015 May; 185(5):1385-95.
    View in: PubMed
    Score: 0.107
  51. Korean version of the functional assessment of cancer therapy (FACT)-vanderbilt cystectomy index (VCI): translation and linguistic. Urol J. 2014 Nov 30; 11(6):1961-7.
    View in: PubMed
    Score: 0.104
  52. Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA. Nat Rev Urol. 2014 Oct; 11(10):589-96.
    View in: PubMed
    Score: 0.103
  53. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2015 Feb; 67(2):241-9.
    View in: PubMed
    Score: 0.103
  54. Impact of complications and hospital-free days on health related quality of life 1 year after radical cystectomy. J Urol. 2014 Nov; 192(5):1360-4.
    View in: PubMed
    Score: 0.101
  55. Incidence and predictors of understaging in patients with clinical T1 urothelial carcinoma undergoing radical cystectomy. BJU Int. 2014 Jun; 113(6):894-9.
    View in: PubMed
    Score: 0.100
  56. Racial variation in the quality of surgical care for bladder cancer. Cancer. 2014 Apr 01; 120(7):1018-25.
    View in: PubMed
    Score: 0.097
  57. Trends in the utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer: results from the National Cancer Database. Urology. 2014 Jan; 83(1):75-80.
    View in: PubMed
    Score: 0.097
  58. Blood loss associated with radical cystectomy: a prospective, randomized study comparing Impact LigaSure vs. stapling device. Urol Oncol. 2014 Jan; 32(1):45.e11-5.
    View in: PubMed
    Score: 0.096
  59. Locoregional small cell carcinoma of the bladder: clinical characteristics and treatment patterns. J Urol. 2014 Feb; 191(2):329-34.
    View in: PubMed
    Score: 0.096
  60. Challenges in the pathology of non-muscle-invasive bladder cancer: a dialogue between the urologic surgeon and the pathologist. Urology. 2013 Jun; 81(6):1123-30.
    View in: PubMed
    Score: 0.093
  61. Screening for bladder cancer: rationale, limitations, whom to target, and perspectives. Eur Urol. 2013 Jun; 63(6):1049-58.
    View in: PubMed
    Score: 0.091
  62. Volume outcomes of cystectomy--is it the surgeon or the setting? J Urol. 2012 Dec; 188(6):2139-44.
    View in: PubMed
    Score: 0.090
  63. Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy. J Urol. 1992 Sep; 148(3):797-801.
    View in: PubMed
    Score: 0.089
  64. ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2013 Jan; 63(1):45-57.
    View in: PubMed
    Score: 0.089
  65. Psychometric characteristics of a condition-specific, health-related quality-of-life survey: the FACT-Vanderbilt Cystectomy Index. Urology. 2012 Jul; 80(1):77-83.
    View in: PubMed
    Score: 0.087
  66. Voiding function in women with orthotopic neobladder urinary diversion. J Urol. 2012 Jul; 188(1):200-4.
    View in: PubMed
    Score: 0.087
  67. Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation. PLoS One. 2012; 7(5):e36669.
    View in: PubMed
    Score: 0.087
  68. Determining factors for hospital discharge status after radical cystectomy in a large contemporary cohort. J Urol. 2011 Jan; 185(1):85-9.
    View in: PubMed
    Score: 0.079
  69. Effect of preoperative nutritional deficiency on mortality after radical cystectomy for bladder cancer. J Urol. 2011 Jan; 185(1):90-6.
    View in: PubMed
    Score: 0.079
  70. Preoperative hydronephrosis predicts extravesical and node positive disease in patients undergoing cystectomy for bladder cancer. J Urol. 2010 May; 183(5):1732-7.
    View in: PubMed
    Score: 0.075
  71. Risk factors for urothelial carcinoma of the prostate in patients undergoing radical cystoprostatectomy for bladder cancer. BJU Int. 2009 Oct; 104(7):934-7.
    View in: PubMed
    Score: 0.070
  72. Comparison of American Joint Committee on Cancer pathologic stage T3a versus T3b urothelial carcinoma: analysis of patient outcomes. Cancer. 2009 Feb 15; 115(4):770-5.
    View in: PubMed
    Score: 0.070
  73. Comparison of american joint committee on cancer pathological stage T2a versus T2b urothelial carcinoma: analysis of patient outcomes in organ confined bladder cancer. J Urol. 2009 Feb; 181(2):540-5; discussion 546.
    View in: PubMed
    Score: 0.069
  74. Association of procedure volume with radical cystectomy outcomes in a nationwide database. J Urol. 2007 Oct; 178(4 Pt 1):1418-21; discussion 1421-2.
    View in: PubMed
    Score: 0.063
  75. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol. 2007 Jul; 178(1):68-73; discussion 73.
    View in: PubMed
    Score: 0.062
  76. Patterns of initial transitional cell recurrence in patients after cystectomy. J Urol. 2006 Jun; 175(6):2054-7.
    View in: PubMed
    Score: 0.058
  77. Urethral recurrence in patients following orthotopic urinary diversion. J Urol. 2004 Oct; 172(4 Pt 1):1338-41.
    View in: PubMed
    Score: 0.052
  78. Outcomes in patients with pathological carcinoma in situ only disease at radical cystectomy. J Urol. 2004 Sep; 172(3):882-4.
    View in: PubMed
    Score: 0.051
  79. Benefit of radical cystectomy in the elderly patient with significant co-morbidities. Urol Oncol. 2004 May-Jun; 22(3):178-81.
    View in: PubMed
    Score: 0.050
  80. Incidence and location of prostate and urothelial carcinoma in prostates from cystoprostatectomies: implications for possible apical sparing surgery. J Urol. 2004 Feb; 171(2 Pt 1):646-51.
    View in: PubMed
    Score: 0.049
  81. Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathological stage. J Urol. 2003 Oct; 170(4 Pt 1):1085-7.
    View in: PubMed
    Score: 0.048
  82. Orthotopic neobladder following radical cystectomy in patients with high perioperative risk and co-morbid medical conditions. J Urol. 2002 Dec; 168(6):2454-6.
    View in: PubMed
    Score: 0.045
  83. Preservation of the anterior vaginal wall during female radical cystectomy with orthotopic urinary diversion: technique and results. J Urol. 2002 Oct; 168(4 Pt 1):1442-5.
    View in: PubMed
    Score: 0.045
  84. Analysis of early complications after radical cystectomy: results of a collaborative care pathway. J Urol. 2002 May; 167(5):2012-6.
    View in: PubMed
    Score: 0.044
  85. Routine postoperative intensive care monitoring is not necessary after radical cystectomy. J Urol. 2002 Mar; 167(3):1321-4.
    View in: PubMed
    Score: 0.043
  86. Robotic Cystectomy with Intracorporeal Urinary Diversion: Review of Current Techniques and Outcomes. Urol Clin North Am. 2018 Feb; 45(1):67-77.
    View in: PubMed
    Score: 0.032
  87. Radical cystectomy in the octogenarian. J Urol. 1997 Dec; 158(6):2113-7.
    View in: PubMed
    Score: 0.032
  88. Upper tract tumors in patients with primary bladder cancer followed for 15 years. J Urol. 1996 Oct; 156(4):1286-7.
    View in: PubMed
    Score: 0.030
  89. Causes of increased length of stay following radical cystectomy. Urol Nurs. 2002 Oct; 22(5):319-23, 339.
    View in: PubMed
    Score: 0.011
  90. Causes of increased hospital stay after radical cystectomy in a clinical pathway setting. J Urol. 2002 Jan; 167(1):208-11.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES